

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING D	ATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/935,135	08/21/2001		Moshe Levin	50094/003001	8828
21559	7590	09/17/2004		EXAMINER	
CLARK & ELBING LLP 101 FEDERAL STREET			CHOOBIN, BARRY		
BOSTON, M				ART UNIT	PAPER NUMBER
2001011, 1111 02110				2625	

DATE MAILED: 09/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

·	Application No.	Applicant(s)					
	09/935,135	LEVIN ET AL.					
Office Action Summary	Examiner	Art Unit					
·	Barry Choobin	2625					
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	e correspondence a	ddress				
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be y within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS free, cause the application to become ABANDO	timely filed lays will be considered time om the mailing date of this of NED (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on	<u>_</u> .						
2a) This action is FINAL . 2b) ☐ This	s action is non-final.						
 Since this application is in condition for allowa closed in accordance with the practice under I 	·		e merits is				
Disposition of Claims							
4)⊠ Claim(s) <u>1-15</u> is/are pending in the application							
4a) Of the above claim(s) is/are withdra							
5) Claim(s) is/are allowed.	÷						
6)⊠ Claim(s) <u>1-9 and 11-15</u> is/are rejected.							
7)⊠ Claim(s) <u>10</u> is/are objected to.							
8) Claim(s) are subject to restriction and/o	or election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examine	er.						
10)⊠ The drawing(s) filed on <u>21 August 2001</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.							
Applicant may not request that any objection to the	drawing(s) be held in abeyance. S	See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correct		=					
11) The oath or declaration is objected to by the Ex	kaminer. Note the attached Office	ce Action or form P	TO-152.				
Priority under 35 U.S.C. § 119							
12)⊠ Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. & 119	(a)-(d) or (f).					
a)⊠ All b)□ Some * c)□ None of:							
1.⊠ Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau	* **						
* See the attached detailed Office action for a list	of the certified copies not recei	ved.					
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summa						
 2)	Paper No(s)/Mail 5) Notice of Informa	Date I Patent Application (PT	O-152)				
Paper No(s)/Mail Date <u>January 28, 2002</u> .	6) Other:						

Art Unit: 2625

DETAILED ACTION

Information Disclosure Statement

1. The information disclosure statement (IDS) submitted on January 28, 2002 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 3. Claims 1, 2, 5, 9, 11 -14 are rejected under 35 U.S.C. 102(e) as being anticipated by Zavislan (US 6,684,092).

As to claim 1, Zavislan discloses a medical decision support system comprising (a system for facilitating pathological examination of a lesion in tissue)

- A computer (column 4, lines 1-2); and

A computer program product arranged (column 4, lines 5-7 wherein a personal computer is programmed to operate in accordance with instructions stored in its memory) to provide data derived from examination of digital images of a tissue specimen (column 4, lines 11-13) according to predetermined criteria for histopathological analysis (column 4, lines 28-30 wherein predetermined criteria

Art Unit: 2625

corresponds to "sufficient resolution for pathological examination of lesion", as to histopatological in claim language versus pathological in prior art, note that they both by definition mean the structural and functional changes produced by the diseases).

As to claim 2, Zavislan discloses a computerized medical decision support system as in claim 1 (see claim 1, above), wherein said computer program product further includes an analysis module (column 3, lines 13-26 wherein the computer generates location information referencing the location in the microscopic picture and the location information, corresponds to analysis module in this claim. Furthermore, Zavislan discloses a pathology computer 14, file structure 80, corresponds to analysis module. See column 7, lines 15-26).

As to claim 5, Zavislan discloses an image acquisition module for providing said digital images (fig.1, 22).

As to claim 9, Zavislan discloses a method for assisting in obtaining a pathological diagnosis from a plurality of pictures representing a specimen on a slide, the method comprising the following steps;

- -Obtaining digitized data corresponding to images of a specimen on a slide placed under a microscope (fig.1, camera 19 and imager 22 both take same images);
- Processing said images (exam computer 12);
- Examining the images in accordance with predetermined histopathological

Art Unit: 2625

Criteria', and

- Providing an examination report based on said examination (the display corresponds to a report or an output).

As to claim 11, Zavislan discloses the method according to claim 9 (see claim 9, above), further comprising;

- Providing an analysis based on said examination (column 3, lines 13-26).

As to claim 12, Zavislan discloses the method according to claim 9 (see claim 9, above), further comprising;

- Providing a diagnosis based on said examination (column 3, lines 5-12).

As to claim 13, Zavislan disclose the method according to claim 9 (see claim 9, above), wherein the step of obtaining digitized data includes obtaining digitized data corresponding to images of a specimen taken at least one magnification (low magnification, column 5, lines 1-4).

As to claim 14, Zavislan disclose the method according to claim 9 (see claim 9, above), wherein the step of obtaining digitized data includes obtaining digitized data corresponding to images of a specimen taken at a plurality of different magnifications (column 5, lines 1-12).

Art Unit: 2625

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 3-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zavislan in view of Papier et al (US 2002/0021828).

As to claim 3, Zavislan discloses a computerized medical decision support system as in claim 2 (see claim 2, above).

Zavislan does not expressly disclose a computer program with a diagnosis module.

Papier et al disclose a system and method to aid diagnoses using crossreferenced knowledge and image database comprising a diagnosis module (page 15, 0267).

Papier et al and Zavislan are combinable because they are from the same field of endeavor, which is to aid or facilitate pathological examination and diagnoses.

At the time of the invention, it would have been obvious to a person of ordinary skill in the art to modify Zavislan with Papier et al to process the characteristic entered to identify, from a plurality of possible causes of death, a subset of causes that are consistent with the characteristics and description entered.

Art Unit: 2625

The suggestion/motivation for doing so would have been to improve the investigation of diagnostic hypotheses and to narrow and create at least one subset of possible diagnoses (page 1, 0005).

Therefore, it would have been obvious to combine Papier et al and Zavislan.

As to claim 4, Papier et al disclose a computerized medical decision support system as in claim 3 (see claim 3) wherein said system further provides data concerning similar cases, including images and related information analysis (page 15, 0267).

Claim Rejections - 35 USC § 103

- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 7. Claims 6-8 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zavislan in view of Weinstein (US 5,297,034).

As to claim 6, Zavislan discloses a computerized medical decision support system as in claim 5 (see claim 5 above),

a microscope (confocal imager corresponds to a microscope).

Zavislan does not expressly disclose a digital camera coupled to said microscope for capturing, through said microscope, at least one picture representing a specimen on a slide and generating digitized images thereof.

Art Unit: 2625

Weinstein discloses Telepathology diagnostic network comprising; a digital camera coupled to said microscope for capturing, through said microscope, at least one picture representing a specimen on a slide and generating digitized images thereof (fig.5) for picking up the magnified image of the specimen and converting it to an electronic video signal (column 8, lines 10-12).

Weinstein is combinable with Zavislan because they both deal with processing specimen image using microscope.

Therefore, it would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify Zavislan with Weinstein in order to convert the microscopic image to video signal for broad band transmission for verification (column 8, lines 10-27).

Therefore, it would have been obvious to combine Weinstein with Zalvislan in order to obtain the invention as specified in claim 6.

As to claim 7, Weinstein discloses the computerized medical decision support system as in claim 6 (see claim 6, above), wherein said digital camera is arranged to capture, through said microscope, more than one picture representing a specimen on a slide and generating digitized images thereof (column 6, lines 3-8).

As to claim 8, Weinstein disclose communication means for transfering data from the digital camera to a remote server for image processing, and from the server back to the computer (column 4, lines 43-47).

Art Unit: 2625

As to claim 15, Weistein discloses mapping elements to permit zooming from images at one magnification to another at an analogous point in the images (column 9, lines 54-62).

Allowable Subject Matter

8. Claim 10 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

CONTACT INFORMATION

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barry Choobin whose telephone number is 703-306-5787. The examiner can normally be reached on M-F 7:30 AM to 18:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bhavesh Mehta can be reached on 703-308-5246. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 2625

Barry Chookin August 25, 2004